PD-1 inhbitor+SHR0302

Phase 2Small molecule

CChunxia Su

PD-1 inhbitor+SHR0302 is one of 4 small molecule programs targeting Immunology. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImmunologyNot yet recruiting

ImmunologyPhase 2

Not yet recruiting

Competition

Competitive Landscape

6 competitors in Immunology

#DrugCompanyPhaseTrials

Nonavalent HPV Vaccine

XXiamen University

Phase 3

1 2

Trivalent Split Inf

Sanofi

Phase 3

1 3

Flumist

AstraZeneca

Phase 1

1 4

PD-1 inhbitor+SHR0302

CChunxia Su

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Not yet recruiting

Immunology

NCT06925048

Clinical

Trials by Indication[1]

Immunology1 trial

SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC

Not yet recruiting·CChunxia Su·Phase 2·NCT06925048·86 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PD-1 inhbitor+SHR0302. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PD-1 inhbitor+SHR0302 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PD-1 inhbitor+SHR0302. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chunxia Su company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CChunxia Su

PD-1 inhbitor+SHR0302

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Immunology1 trial

References

Drug Info

Quick Facts

Related News